問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Others-

Division of Hematology & Oncology

Division of General Internal Medicine

National Taiwan University Cancer Center (在職)

Division of Hematology & Oncology

更新時間：2023-09-19

劉家豪
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

17Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

劉家豪

List

41Cases

2019-11-30 - 2022-05-19

Phase III

A Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis who were Previously Treated with JAK Inhibitor Therapy

  • Condition/Disease

    Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis

  • Test Drug

    Momelotinib Tablets；Danazol Capsules

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2016-09-08 - 2019-10-31

Phase III

A randomized, double-blind phase 3 study of vadastuximab talirine (SGN-CD33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML)

  • Condition/Disease

    Acute Myeloid Leukemia (AML)

  • Test Drug

    Vadastuximab Talirine

Participate Sites
4Sites

Terminated4Sites

蕭樑材
Taipei Veterans General Hospital

2021-05-10 - 2022-09-26

Phase II

A Phase 1/2 Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 701 Monotherapy, or in Combination with Pomalidomide with and without Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (ParadigMM-1B)

  • Condition/Disease

    Relapsed/Refractory Multiple Myeloma

  • Test Drug

    AMG701

Participate Sites
3Sites

Terminated3Sites

2015-10-30 - 2019-04-27

Phase II

A Phase 2, Open-label, Multiple Ascending Dose Study to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients with Paroxysmal Nocturnal Hemoglobinuria

  • Condition/Disease

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

  • Test Drug

    ALXN1210

Participate Sites
2Sites

Terminated2Sites

2016-07-31 - 2022-06-30

Phase II/III

A Phase 2/3 Multicenter, Open-label, 3 arm, 2 stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

  • Condition/Disease

    Acute Myeloid Leukemia (AML)

  • Test Drug

    ASP2215

Participate Sites
9Sites

Recruiting2Sites

Terminated7Sites

2016-11-01 - 2020-12-31

Phase II

A Phase 1b/Randomized Phase 2 Study to Evaluate LY3039478 in Combination with Dexamethasone in T-ALL/T-LBL Patients

  • Condition/Disease

    T-cell Acute lymphoblastic leukemia(T-ALL)/r T-cell lymphoblastic lymphoma (T-LBL)

  • Test Drug

    LY3039478

Participate Sites
3Sites

Terminated2Sites

2016-03-31 - 2021-12-31

Phase III

A randomized, double blind, placebo-controlled, multi-center, Phase III study investigating the efficacy and safety of ruxolitinib in Early Myelofibrosis patients with high molecular risk mutations

  • Condition/Disease

    Early Myelofibrosis

  • Test Drug

    JAKAVI

Participate Sites
3Sites

Terminated3Sites

2015-06-01 - 2017-09-30

Phase II

A multi-center, randomized, double-blind, placebo controlled, study to evaluate the efficacy and safety of CSJ148 compared to placebo to prevent human cytomegalovirus (HCMV) replication in stem cell transplant patients

  • Condition/Disease

    prevent human cytomegalovirus (HCMV) replication in stem cell transplant patients

  • Test Drug

    CSJ148

Participate Sites
4Sites

Terminated3Sites

2017-02-10 - 2020-01-30

Phase III

A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Subjects With New Onset Chronic Graft Versus Host Disease (cGVHD)

  • Condition/Disease

    Chronic Graft Versus Host Disease (cGVHD)

  • Test Drug

    Imbruvica®

Participate Sites
3Sites

Terminated2Sites

2016-07-01 - 2018-05-03

Phase I

An open label, phase I trial of intravenous administration of volasertib as monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome after hypomethylating agents treatment failure

  • Condition/Disease

    myelodysplastic syndrome, MDS

  • Test Drug

    Volasertib

Participate Sites
3Sites

Terminated2Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB